Granules India Limited (GRANULES.NS)
Granules India Limited operates in the Drug Manufacturers - Specialty & Generic industry of the Healthcare sector, headquartered in Hyderabad, TS, IN. The stock last traded at $858.40, up 0.10% on the session, giving a market capitalisation of $212.71B. Its beta of 0.06 implies it has historically moved less than the broad market.
Founded in 1984 and headquartered in Hyderabad, India, Granules India Limited operates as a key player in the pharmaceutical sector. The company is engaged in the manufacturing and global distribution of a diverse range of pharmaceutical products, including active pharmaceutical ingredients (APIs), intermediate compounds for drug formulation, and final dosage forms (FDFs). Its API portfolio addresses various therapeutic categories, such as antiviral medications, treatments for hypertension, antihistamines, anti-infectives, pain relief agents, anticoagulants, anti-fibrinolytic drugs, and platelet inhibitors. Additionally, Granules produces a variety of FDFs, encompassing tablets, caplets, and press-fit capsules, which are supplied in bulk, blister packs, and bottles. The firm also develops specialized products for oncology. Granules India Limited maintains a broad international presence, with its products reaching markets across India, North America, Europe, Latin America, Africa, and the Middle East.
Granules India Limited is most often compared with the following Healthcare names: